Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SINGAPORE EXCHANGE  >  Luye Pharma Group Ltd    LUYE   BMG5722Z1014

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

LUYE PHRM : Exercise Of The Call Option By Luye Biotech (Singapore) Pte Ltd Under The Investment Agreement To Acquire All The Shares Held By Biomedical Sciences Investment Fund Pte Ltd In The Issued Share Capital Of A-Bio Pharma Pte Ltd

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 12:35pm CEST

LUYE PHARMA GROUP LTD.

(INCORPORATED IN BERMUDA)

EXERCISE OF THE CALL OPTION BY LUYE BIOTECH (SINGAPORE) PTE LTD UNDER THE INVESTMENT AGREEMENT TO ACQUIRE ALL THE SHARES HELD BY BIOMEDICAL SCIENCES INVESTMENT FUND PTE LTD IN THE ISSUED SHARECAPITAL OF A-BIO PHARMA PTE LTD

Where capitalised terms are used in this announcement and not otherwise defined, such capitalised terms shall bear the same meanings as ascribed to them in the Company?s announcement dated

30 July 2010 in relation to the Strategic Investment in A-Bio Pharma Pte Ltd by Luye-Biotech

(Singapore) Pte Ltd.

The Board of Directors of Luye Pharma Group Ltd. (?Luye? or ?the Company?) is pleased to announce that Luye Biotech, a wholly-owned subsidiary of the Company, has exercised the Call Option under the Investment Agreement to acquire all of BMSIF?s shares comprising (i) one (1) ordinary share and (ii) 2,500,000 preference shares (Series B Preferred Shares) (collectively known as the ?Call Option Shares?) in A-Bio Pharma Pte Ltd (?A-Bio?) at a Option Consideration of S$2,750,000.

When the acquisition is completed, the Company will own 100% of the entire issued share capital of A-Bio through another wholly-owned subsidiary, Shandong Luye Pharmaceutical Co. Ltd.

The Option Consideration will funded by internal resources and is not expected to have any material impact on the net tangible assets per share and earnings per share of the Company for the current financial year ending 31 December 2011.

None of the Directors or controlling shareholders has any interest, directly or indirectly, in the transaction.

By Order of the Board

Liu Dianbo

Executive Chairman

Date: 25 July 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LUYE PHARMA GROUP LTD
09/02 LUYE PHARMA : Announces 2016 Interim Results
09/01 LUYE PHARMA : “The core of Luye's strategy lies in growth, and the key dri..
08/09 LUYE PHARMA : Approval for clinical trial for new drug goserelin acetate extende..
07/26 LUYE PHARMA : Takes a Milestone Step Forward; Proposed Acquisition of Acino`s TD..
07/26 LUYE PHARMA : to buy TDS business at EUR245m
07/26 LUYE PHARMA : Buys Europe TDS Makers
07/26 LUYE PHARMA : Singapore-based Luye Medical Group Signs MOU with China's City of ..
07/26 LUYE PHARMA : Takes a Milestone Step Forward Proposed Acquisition of Acino&rsquo..
07/26 LUYE PHARMA : Takes a Milestone Step Forward; Proposed Acquisition of Acino's TD..
07/25 LUYE PHARMA : Discloseable transaction - proposed acquisition of acino's transde..
More news
Sector news : Generic Pharmaceuticals
09:39p MYLAN : faces scrutiny over EpiPen profit data shown to Congress
05:36pDJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
05:36pDJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress
04:45pDJPfizer Throws Out Plan to Split Into Two Companies
01:53pDJPFIZER : Won't Pursue a Split of Established and New Medical Lines -- Update
More sector news : Generic Pharmaceuticals
Advertisement
Financials ( CNY)
Sales 2016 2 818 M
EBIT 2016 992 M
Net income 2016 874 M
Finance 2016 1 829 M
Yield 2016 -
P/E ratio 2016 17,01
P/E ratio 2017 14,95
EV / Sales 2016 4,65x
EV / Sales 2017 4,06x
Capitalization 14 923 M
More Financials
Chart LUYE PHARMA GROUP LTD
Duration : Period :
Luye Pharma Group Ltd Technical Analysis Chart | LUYE | BMG5722Z1014 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 5,49  CNY
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Dian Bo Liu Executive Chairman & Chief Executive Officer
Yu Bo Liu Chief Operating Officer, VP & Head-Human Resources
Yuan Chong Liu Chief Financial Officer
You Xin Li Vice President, Head-Research & Development
Hui Xian Yuan Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LUYE PHARMA GROUP LTD0.00%2 238
SUN PHARMACEUTICAL IND..-5.02%28 165
OTSUKA HOLDINGS CO LTD5.33%25 163
BIOMARIN PHARMACEUTICA..-7.03%16 634
ONO PHARMACEUTICAL CO...-34.35%15 857
ASPEN PHARMACARE HOLDI..2.85%10 757
More Results